Comparison of insulins detemir and glargine: Effects on glucose disposal, hepatic glucose release and the central nervous system

Diabetes, Obesity and Metabolism

Volumn 13, Issue 9, 2011, Pages 832-840

  Moore, M C ^a   Smith, M S ^a   Turney, M K ^a   Boysen, S ^b   Williams, P E ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NOVO NORDISK A S   (Denmark)

Author keywords

Hepatic glucose production; Insulin analogues; Insulin signalling; Insulin therapy; Liver; STAT3

Indexed keywords

FATTY ACID; GLUCOSE; INSULIN; INSULIN DETEMIR; INSULIN GLARGINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAROTID ARTERY; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DOG; DRUG ADMINISTRATION ROUTE; DRUG EFFECT; DRUG MEGADOSE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; HYPERINSULINEMIA; HYPOTHALAMUS; INFUSION RATE; INSULIN TREATMENT; LIVER; LOW DRUG DOSE; MALE; NONHUMAN; PERIPHERAL VEIN; PORTAL VEIN; VERTEBRAL ARTERY;

EID: 79960826090     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2011.01418.x     Document Type: Article

References (50)

1. Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis. Diabetes Obes Metab 2009; 11: 372-378.
2. Cherrington AD, Sindelar D, Edgerton D, Steiner K, McGuinness OP. Physiological consequences of phasic insulin release in the normal animal. Diabetes 2002; 51 Suppl 1: S103-108.
3. Smeeton F, Shojaee Moradie F, Jones RH et al. Differential effects of insulin detemir and neutral protamine Hagedorn (NPH) insulin on hepatic glucose production and peripheral glucose uptake during hypoglycaemia in type 1 diabetes. Diabetologia 2009; 52: 2317-2323.
4. Obici S, Zhang BB, Karkanias G, Rossetti L. Hypothalamic insulin signaling is required for inhibition of glucose production. Nat Med 2002; 8: 1376-1382.
5. Hennige AM, Sartorius T, Tschritter O et al. Tissue selectivity of insulin detemir action in vivo. Diabetologia 2006; 49: 1274-1282.
6. Hamilton-Wessler M, Ader M, Dea M et al. Mechanism of protracted metabolic effects of fatty acid acylated insulin, NN304, in dogs: retention of NN304 by albumin. Diabetologia 1999; 42: 1254-1263.
7. Hordern SVM, Wright JE, Umpleby AM et al. Comparison of the effects on glucose and lipid metabolism of equipotent doses of insulin detemir and NPH insulin with a 16-h euglycaemic clamp. Diabetologia 2005; 48: 420-426.
8. Edgerton DS, Lautz M, Scott M et al. Insulin's direct effects on the liver dominate the control of hepatic glucose production. J Clin Invest 2006; 116: 521-527.
9. Giacca A, Fisher SJ, McCall RH, Shi ZQ, Vranic M. Direct and indirect effects of insulin in suppressing glucose production in depancreatized dogs: role of glucagon. Endocrinology 1997; 138: 999-1007.
10. Gupta N, Sandhu H, Goh T et al. Insulin inhibits glucose production by a direct effect in diabetic depancreatized dogs during euglycemia. Am J Physiol Endocrinol Metab 2002; 283: E1002-1007.
11. Sindelar DK, Balcom JH, Chu CA, Neal DW, Cherrington AD. A comparison of the effects of selective increases in peripheral or portal insulin on hepatic glucose production in the conscious dog. Diabetes 1996; 45: 1594-1604.
12. Pagliassotti MJ, Holste LC, Moore MC, Neal DW, Cherrington AD. Comparison of the time courses of insulin and the portal signal on hepatic glucose and glycogen metabolism in the conscious dog. J Clin Invest 1996; 97: 81-91.
13. Biggers DW, Myers SR, Neal D et al. Role of brain in counterregulation of insulin-induced hypoglycemia in dogs. Diabetes 1989; 38: 7-16.
14. Kurtzhals P, Havelund S, Jonassen I et al. Albumin binding and time action of acylated insulins in various species. J Pharm Sci 1996; 85: 304-308.
15. Sørensen AR, Stidsen CE, Ribel U et al. Insulin detemir is a fully efficacious, low affinity agonist at the insulin receptor. Diabetes Obes Metab 2010; 12: 665-673.
16. Moore MC, Satake S, Lautz M et al. Nonesterified fatty acids and hepatic glucose metabolism in the conscious dog. Diabetes 2004; 53: 32-40.
17. Poulsen F, Jensen KB. A luminescent oxygen channeling immunoassay for the determination of insulin in human plasma. J Biomol Screen 2007; 12: 240-247.
18. Wang Z, Hedrington MS, Gogitidze Joy N et al. Dose-response effects of insulin glargine in type 2 diabetes. Diabetes Care 2010; 33: 1555-1560.
19. Hsieh PS, Moore MC, Neal DW, Emshwiller M, Cherrington AD. Rapid reversal of the effects of the portal signal under hyperinsulinemic conditions in the conscious dog. Am J Physiol 1999; 276: E930-E937.
20. Dobbins RL, Davis SN, Neal DW et al. Compartmental modeling of glucagon kinetics in the conscious dog. Metabolism 1995; 44: 452-459.
21. Mari A. Estimation of the rate of appearance in the non-steady state with a two-compartment model. Am J Physiol 1992; 263: E400-E415.
22. Baskin DG, Porte D Jr, Guest K, Dorsa DM. Regional concentrations of insulin in the rat brain. Endocrinology 1983; 112: 898-903.
23. Davis SN, Colburn C, Dobbins R et al. Evidence that the brain of the conscious dog is insulin sensitive. J Clin Invest 1995; 95: 593-602.
24. Davis SN, Dunham B, Walmsley K et al. Brain of the conscious dog is sensitive to physiological changes in circulating insulin. Am J Physiol 1997; 272: E567-E575.
25. Kurtzhals P, Havelund S, Jonassen I et al. Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo. Biochem J 1995; 312(Pt 3): 725-731.
26. Markussen J, Havelund S, Kurtzhals P et al. Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs. Diabetologia 1996; 39: 281-288.
27. Field JB. Extraction of insulin by liver. Annu Rev Med 1973; 24: 309-314.
28. Kaden M, Harding P, Field JB. Effect of intraduodenal glucose administration on hepatic extraction of insulin in the anesthetized dog. J Clin Invest 1973; 52: 2016-2028.
29. Polonsky K, Jaspan J, Emmanouel D, Holmes K, Moossa AR. Differences in the hepatic and renal extraction of insulin and glucagon in the dog: evidence for saturability of insulin metabolism. Acta Endocrinol (Copenh) 1983; 102: 420-427.
30. Rojdmark S, Bloom G, Chou MC, Field JB. Hepatic extraction of exogenous insulin and glucagon in the dog. Endocrinology 1978; 102: 806-813.
31. Dea MK, Hamilton-Wessler M, Ader M et al. Albumin binding of acylated insulin (NN304) does not deter action to stimulate glucose uptake. Diabetes 2002; 51: 762-769.
32. Gilor C, Ridge TK, Attermeier KJ, Graves TK. Pharmacodynamics of insulin detemir and insulin glargine assessed by an isoglycemic clamp method in healthy cats. J Vet Intern Med 2010; 24: 870-874.
33. Sørensen LP, Brock B, Mengel A et al. Similarity of pharmacodynamic effects of a single injection of insulin glargine, insulin detemir and NPH insulin on glucose metabolism assessed by 24-h euglycaemic clamp studies in healthy humans. Diabet Med 2010; 27: 830-837.
34. Rosskamp RH, Park G. Long-acting insulin analogs. Diabetes Care 1999; 22 Suppl 2: B109-113.
35. Mudaliar S, Mohideen P, Deutsch R et al. Intravenous glargine and regular insulin have similar effects on endogenous glucose output and peripheral activation/deactivation kinetic profiles. Diabetes Care 2002; 25: 1597-1602.
36. Edgerton DS, Cardin S, Emshwiller M et al. Small increases in insulin inhibit hepatic glucose production solely caused by an effect on glycogen metabolism. Diabetes 2001; 50: 1872-1882.
37. Edgerton DS, Cardin S, Pan C et al. Effects of insulin deficiency or excess on hepatic gluconeogenic flux during glycogenolytic inhibition in the conscious dog. Diabetes 2002; 51: 3151-3162.
38. Huang XF, Xin X, McLennan P, Storlien L. Role of fat amount and type in ameliorating diet-induced obesity: insights at the level of hypothalamic arcuate nucleus leptin receptor, neuropeptide Y and pro-opiomelanocortin mRNA expression. Diabetes Obes Metab 2004; 6: 35-44.
39. Oh IS, Shimizu H, Sato T et al. Molecular mechanisms associated with leptin resistance: n-3 polyunsaturated fatty acids induce alterations in the tight junction of the brain. Cell Metab 2005; 1: 331-341.
40. Wang H, Storlien LH, Huang XF. Effects of dietary fat types on body fatness, leptin, and ARC leptin receptor, NPY, and AgRP mRNA expression. Am J Physiol Endocrinol Metab 2002; 282: E1352-1359.
41. Stumvoll M, Jacob S, Wahl HG et al. Suppression of systemic, intramuscular, and subcutaneous adipose tissue lipolysis by insulin in humans. J Clin Endocrinol Metab 2000; 85: 3740-3745.
42. Scherer T, O'Hare J, Diggs-Andrews K et al. Brain insulin controls adipose tissue lipolysis and lipogenesis. Cell Metab 2011; 13: 183-194.
43. Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol 2006; 7: 85-96.
44. Inoue H, Ogawa W, Asakawa A et al. Role of hepatic STAT3 in brain-insulin action on hepatic glucose production. Cell Metab 2006; 3: 267-275.
45. Inoue H, Ogawa W, Ozaki M et al. Role of STAT-3 in regulation of hepatic gluconeogenic genes and carbohydrate metabolism in vivo. Nat Med 2004; 10: 168-174.
46. Erion DM, Yonemitsu S, Nie Y et al. SirT1 knockdown in liver decreases basal hepatic glucose production and increases hepatic insulin responsiveness in diabetic rats. Proc Natl Acad Sci U S A 2009; 106: 11288-11293.
47. Banks WA, Morley JE, Lynch JL, Lynch KM, Mooradian AD. Insulin detemir is not transported across the blood-brain barrier. Peptides 2010; 31: 2284-2248.
48. Gupta G, Cases JA, She L et al. Ability of insulin to modulate hepatic glucose production in aging rats is impaired by fat accumulation. Am J Physiol Endocrinol Metab 2000; 278: E985-991.
49. Exton JH. Hormonal control of gluconeogenesis. Adv Exp Med Biol 1979; 111: 125-167.
50. Ramnanan CJ, Edgerton DS, Rivera N et al. Molecular characterization of insulin-mediated suppression of hepatic glucose production in vivo. Diabetes 2010; 59: 1302-1311.